Efficacy and safety of prophylaxis with BAY 81‐8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial

por Yang, Renchi, Sun, Jing, Zhao, Yongqiang, Wang, Xuefeng, Wu, Depei, Tseneklidou‐Stoeter, Despina, Wu, Junde, Church, Nikki
Publicado 2019

BAY 81‐8973 demonstrated efficacy, safety and joint status improvement in patients with severe haemophilia A in the LEOPOLD I extension for ≤2 years

por Mahlangu, Johnny, Lopez Fernandez, Maria Fernanda, Santagostino, Elena, Lalezari, Shadan, Tseneklidou‐Stoeter, Despina, Beckmann, Horst, Church, Nikki
Publicado 2020

PROTECT VIII kids extension study: Long‐term safety and efficacy of BAY 94‐9027 (damoctocog alfa pegol) in children with severe haemophilia A

por Mancuso, Maria Elisa, Biss, Tina, Fischer, Kathelijn, Maas Enriquez, Monika, Steele, MacGregor, Wang, Maria, Tseneklidou‐Stoeter, Despina, Ahuja, Sanjay, Kenet, Gili
Publicado 2021

BAY 81-8973 Efficacy and Safety in Previously Untreated and Minimally Treated Children with Severe Hemophilia A: The LEOPOLD Kids Trial

por Ljung, Rolf, Chan, Anthony K. C., Glosli, Heidi, Afonja, Olubunmi, Becker, Bastian, Tseneklidou-Stoeter, Despina, Mancuso, Maria Elisa, Saulyte-Trakymiene, Sonata, Kenet, Gili
Publicado 2023

BAY 94‐9027 prophylaxis is efficacious and well tolerated for up to >5 years with extended dosing intervals: PROTECT VIII extension interim results

por Lalezari, Shadan, Reding, Mark T., Pabinger, Ingrid, Holme, Pal Andre, Negrier, Claude, Chalasani, Pavani, Shin, Ho‐Jin, Wang, Maria, Tseneklidou‐Stoeter, Despina, Maas Enriquez, Monika
Publicado 2019